A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
about
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibitBiology of the major facilitative folate transporters SLC19A1 and SLC46A1Vitamin D is not linked to folate status and mRNA expression of intestinal proton-coupled folate transporter.The proton-coupled folate transporter: physiological and pharmacological roles.Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorptionMechanisms of membrane transport of folates into cells and across epithelia.Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporterIdentification and functional impact of homo-oligomers of the human proton-coupled folate transporter.Augmentation of reduced folate carrier-mediated folate/antifolate transport through an antiport mechanism with 5-aminoimidazole-4-carboxamide riboside monophosphateThe human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors.Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors.The intestinal absorption of folates.Improvement of pharmacokinetic and antitumor activity of layered double hydroxide nanoparticles by coating with PEGylated phospholipid membrane.Functional roles of aspartate residues of the proton-coupled folate transporter (PCFT-SLC46A1); a D156Y mutation causing hereditary folate malabsorption.Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.Vulnerability of the cysteine-less proton-coupled folate transporter (PCFT-SLC46A1) to mutational stress associated with the substituted cysteine accessibility method.N-linked glycosylation and its impact on the electrophoretic mobility and function of the human proton-coupled folate transporter (HsPCFT).The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorptionHypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line.Random mutagenesis of the proton-coupled folate transporter (SLC46A1), clustering of mutations, and the bases for associated losses of functionIdentification of Tyr residues that enhance folate substrate binding and constrain oscillation of the proton-coupled folate transporter (PCFT-SLC46A1).Determinants of the activities of antifolates delivered into cells by folate-receptor-mediated endocytosis.A P425R mutation of the proton-coupled folate transporter causing hereditary folate malabsorption produces a highly selective alteration in folate binding.Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.Identification of a functionally critical GXXG motif and its relationship to the folate binding site of the proton-coupled folate transporter (PCFT-SLC46A1)Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption.Drug delivery strategies for cathepsin inhibitors in joint diseases.A humanized mouse model for the reduced folate carrier.Identification of an Extracellular Gate for the Proton-coupled Folate Transporter (PCFT-SLC46A1) by Cysteine Cross-linking.Role of the fourth transmembrane domain in proton-coupled folate transporter function as assessed by the substituted cysteine accessibility method.Inhibition of the proton-coupled folate transporter (PCFT-SLC46A1) by bicarbonate and other anions.A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis.Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter.The antifolatesThe membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitorRole of the glutamate 185 residue in proton translocation mediated by the proton-coupled folate transporter SLC46A1.Enhanced receptor-mediated endocytosis and cytotoxicity of a folic acid-desacetylvinblastine monohydrazide conjugate in a pemetrexed-resistant cell line lacking folate-specific facilitative carriers but with increased folate receptor expression
P2860
Q24631090-CFE8D27A-561E-463A-A0D6-310BDBAD51EBQ26998717-3FB55D73-A454-4FF6-A6E9-F1EE4F651667Q30317669-E8509589-094A-4B99-8392-D0075B5E139DQ33908502-90CA4690-9199-4A66-A0EC-FFBA7061AE38Q34129760-D1B97429-F68E-4FFB-B2B0-D778DB5155C3Q34184787-1F1FE7E1-935D-4E62-ABCD-1E9D8E66D92BQ34218576-36B07C61-A5D0-4DA5-8A33-8C6399B02CCCQ34241413-85F19BBE-342F-4405-8F13-FE3564D13A0BQ34272508-69B54A34-AC39-4EC7-ADBF-7F24B5B6BC91Q34297931-1D4F0331-39B6-4B1B-89CB-B4A8BB31BB25Q34310128-C84F3A33-598C-4CCA-904B-79497F020F40Q34333704-546AEB09-EE21-44D6-88E3-D9D0CD90C782Q34403349-47DF4D42-E913-418F-BA5D-6C31BE2CDB78Q34415617-9327AF24-0A0E-4D9D-8FB5-C05F34D409E5Q34450436-A7AC5BAD-A3C1-447F-85E7-5F1B62D13274Q34471848-15F2D378-BE2C-4C82-B918-6CEE16A04337Q34658009-F1332E5B-97A5-402C-8996-155C28BB697CQ34708758-3FDEFADE-D8E6-4D6B-B737-ED0458E9E4D0Q34769345-CE61EEF6-85D1-4ED0-A1B6-D54C1BF07434Q34784792-CCB4E80F-C01A-4023-B17E-4FC8FD524FFCQ34851106-A9BC879E-2036-415A-911C-9B3F7C545125Q34996747-073C4990-28EF-4756-B1A2-2D8087642929Q35085104-481E6C5E-AB27-401F-BC2A-D37EEED0BC24Q35437120-EE662913-7A66-48B4-B4EF-B55B500BD50EQ35639774-A78D3225-72E9-40BA-A599-553C8DA334FDQ35993489-FC45CE81-4116-40F2-ABDE-7020C0883060Q36294436-276A32EF-A173-4368-B6E1-E1F6F832EB5FQ36308965-23886DCB-89EA-4857-9EB9-23448B3687EDQ36312791-4D1903FC-F69D-4EA4-B00F-FF589275B762Q36316921-E836309C-3513-4837-9C9F-EBBA9C70147BQ36503000-19A3C9F4-071C-4124-B279-93D067FAA1F6Q36778842-D7F9AEE3-81F4-4B4A-ACA7-4BA069F90E73Q36923565-CD4CA39A-E831-4ED5-9CB0-2AF65E463D53Q36935269-EACC3783-B65A-4F01-9B7E-6961289AA3B7Q37094213-38CB3682-1F2D-4CFF-8E98-04975D1B37DDQ37162634-BD1F26E7-F395-43E1-9478-309BFE8F60B6Q37183495-442DDFD7-E3E9-48FE-85DB-7EF94E694593Q37200566-1F1ADB95-5E0B-4E4C-9E09-602C5B66CCC9Q37264121-712C92E8-C2B1-4E67-BA3E-4CAEC2564C1EQ37553497-C6AC22E0-11D9-44A7-9549-BFADB6A25433
P2860
A prominent low-pH methotrexate transport activity in human solid tumors: contribution to the preservation of methotrexate pharmacologic activity in HeLa cells lacking the reduced folate carrier.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@ast
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@en
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@nl
type
label
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@ast
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@en
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@nl
prefLabel
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@ast
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@en
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@nl
P2093
P1476
A prominent low-pH methotrexat ...... ng the reduced folate carrier.
@en
P2093
I David Goldman
Marie Hanscom
Rongbao Zhao
P304
P356
10.1158/1078-0432.CCR-1066-03
P407
P577
2004-01-01T00:00:00Z